67-43-6 Usage
Chemical Properties
Different sources of media describe the Chemical Properties of 67-43-6 differently. You can refer to the following data:
1. solid
2. Pentetic acid occurs as a white crystalline solid and is almost
odorless.
3. Diethylenetriaminepentaacetic acid is a solid.
Uses
Different sources of media describe the Uses of 67-43-6 differently. You can refer to the following data:
1. Diethylenetriaminepentaacetic acid is used as chelating agent and forms complexes with metal ions. It finds application as a magnetic resonance imaging (MRI) contrasting agent, since it improves the image by forming a complex with a gadolinium ion. It can also be used for treatment of radioactive materials such as plutonium, americium and other actinides. It is an active component of manganese and zinc fertilizers used in agrochemical industry. It acts as a color inhibitor and is used in the production of acrylon. It is also used in soaps as a water softener.
2. chelating agent, diagnostic aid
3. Diethylenetriaminepentaacetic Acid is a component of manganese and zinc fertilizers.
Production Methods
Pentetic acid is a pentaacetic acid triamine formed during the
preparation of the amino carboxylic acid and its salt.
General Description
Visit our Titration Center to learn more.
Pharmaceutical Applications
Pentetic acid is mainly used as a chelating agent in the preparation
of imaging and contrast agents for radionuclide and magnetic
resonance imaging.It is also used as a carrier excipient for
neutron-capture isotopes in, for example, radiotherapy.Pentetic
acid–isotope complexes have also been considered as model active
substances in scintigraphic imaging studies.Pentetic acid has been
used to chelate metal ions to reduce formation of reactive oxygen
species during lyophilization.
Safety Profile
Moderately toxic by
intraperitoneal route. When heated to
decomposition it emits toxic fumes of NOx.
Safety
Pentetic acid is used in intrathecal and intravenous injection
preparations. The pure form of pentetic acid is moderately toxic
by the intraperitoneal route.
LD50 (mouse, IP): 0.54 g/kg
LD50 (mouse, oral): 4.84 g/kg
storage
The activity of pentetic acid as a chelating agent may cause
unwanted effects in formulations containing metal ions. The desired
chelate may be displaced by other ions from the formulation.
Purification Methods
Crystallise DTPA from water. Dry under vacuum or at 110o. [Bielski & Thomas J Am Chem Soc 109 7761 1987, NMR: Wenzel et al. Anal Chem 54 615 1982, Beilstein 4 IV 2454.]
Incompatibilities
The activity of pentetic acid as a chelating agent may cause
unwanted effects in formulations containing metal ions. The desired
chelate may be displaced by other ions from the formulation.
Regulatory Status
Included in the FDA Inactive Ingredients Database (intrathecal and
intravenous injections). Included in intravenous and intra-articular
injections licensed in the UK.
Check Digit Verification of cas no
The CAS Registry Mumber 67-43-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 7 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 67-43:
(4*6)+(3*7)+(2*4)+(1*3)=56
56 % 10 = 6
So 67-43-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H13N3.5C2H4O2/c5-1-3-7-4-2-6;5*1-2(3)4/h7H,1-6H2;5*1H3,(H,3,4)
67-43-6Relevant articles and documents
Lightening Agents and/or Dyes that Contain Aldehyde(s)
-
, (2010/12/29)
Agents for dyeing and/or lightening keratin fibers, in particular human hair, containing, relative to the weight thereof, 0.001 to 15 wt. % of at least one aldehyde of the formula (I): wherein X represents —CH(R2)—SO2—Y—R1, —CR3R4R5, or wherein Y represents —CH(CHO)— or —CH2— or a chemical bond, and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 independently represents —H or —CN or —F or —Cl or —Br or —I or —CHO or —NH2 or —NO2 or —CF3 or —CCl3 or —CF2CF3 or —CCl2CCl3 or an optionally substituted (C1-C6) alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C1-C6) alkylene group, and wherein the agent contains no oxidation dye precursors of developer and coupler type.
Imaging thrombus with glycoprotein llb/llla antagonists
-
, (2008/06/13)
This invention relates to a method of using a radiolabeled small molecule antagonist of the platelet IIb/IIIa receptor for the diagnosis of arterial and venous thrombi.
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
-
, (2008/06/13)
This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
